Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biotechnology Stocks Profiles

View company profiles of publicly traded biotechnology stocks, and biotech-related stocks.
Tue, Apr 13th, 2021

Moderna Inc (MRNA)

Full Profile

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.

52-Week Low
52-Week High
31.71
189.26

Overview:

Market Capitalization, $K 56,441,980
Shares Outstanding, K 400,525
Last Quarter Sales 570,750 K
Last Quarter Net Income -272,490 K
% Insider Shareholders 19.40%
% Institutional Shareholders 49.83%

Abbvie Inc (ABBV)

Full Profile

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.

52-Week Low
52-Week High
78.66
113.41

Overview:

Market Capitalization, $K 189,789,408
Shares Outstanding, K 1,764,826
Last Quarter Sales 13,858 M
Last Quarter Net Income 36,000 K
% Insider Shareholders 0.09%
% Institutional Shareholders 67.65%

Abbott Laboratories (ABT)

Full Profile

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

52-Week Low
52-Week High
83.52
128.54

Overview:

Market Capitalization, $K 214,177,856
Shares Outstanding, K 1,771,529
Last Quarter Sales 10,701 M
Last Quarter Net Income 2,162 M
% Insider Shareholders 1.50%
% Institutional Shareholders 73.64%

Vanda Pharmaceuticals (VNDA)

Full Profile

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

52-Week Low
52-Week High
9.00
20.51

Overview:

Market Capitalization, $K 891,849
Shares Outstanding, K 54,883
Last Quarter Sales 67,650 K
Last Quarter Net Income 8,190 K
% Insider Shareholders 5.90%
% Institutional Shareholders N/A

Sanofi-Aventis S.A. (SNY)

Full Profile

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.

52-Week Low
52-Week High
43.17
55.00

Overview:

Market Capitalization, $K 127,836,016
Shares Outstanding, K 2,517,944
Last Quarter Sales 11,190 M
Last Quarter Net Income 1,289 M
% Insider Shareholders 1.00%
% Institutional Shareholders 6.94%

Novartis Ag (NVS)

Full Profile

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.

52-Week Low
52-Week High
77.04
98.52

Overview:

Market Capitalization, $K 200,375,680
Shares Outstanding, K 2,288,700
Last Quarter Sales 13,030 M
Last Quarter Net Income 2,094 M
% Insider Shareholders 0.01%
% Institutional Shareholders 9.93%

Glaxosmithkline Plc (GSK)

Full Profile

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.

52-Week Low
52-Week High
33.26
43.18

Overview:

Market Capitalization, $K 98,683,608
Shares Outstanding, K 2,692,595
Last Quarter Sales 11,509 M
Last Quarter Net Income 961,800 K
% Insider Shareholders 10.00%
% Institutional Shareholders 11.18%

Alexion Pharm Inc (ALXN)

Full Profile

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

52-Week Low
52-Week High
94.82
162.60

Overview:

Market Capitalization, $K 34,078,636
Shares Outstanding, K 219,848
Last Quarter Sales 1,592 M
Last Quarter Net Income 535,800 K
% Insider Shareholders 4.03%
% Institutional Shareholders 87.73%

Astrazeneca Plc (AZN)

Full Profile

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.

52-Week Low
52-Week High
45.39
64.94

Overview:

Market Capitalization, $K 131,072,168
Shares Outstanding, K 2,624,593
Last Quarter Sales 7,410 M
Last Quarter Net Income 1,012 M
% Insider Shareholders N/A
% Institutional Shareholders 14.98%

Bristol-Myers Squibb Company (BMY)

Full Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in New York.

52-Week Low
52-Week High
54.07
67.16

Overview:

Market Capitalization, $K 139,866,224
Shares Outstanding, K 2,233,928
Last Quarter Sales 11,068 M
Last Quarter Net Income -10,027 M
% Insider Shareholders 0.11%
% Institutional Shareholders 74.12%

Vertex Pharmaceutic (VRTX)

Full Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

52-Week Low
52-Week High
202.57
306.08

Overview:

Market Capitalization, $K 55,462,464
Shares Outstanding, K 259,960
Last Quarter Sales 1,628 M
Last Quarter Net Income 604,190 K
% Insider Shareholders 0.70%
% Institutional Shareholders 92.01%

Novavax Inc (NVAX)

Full Profile

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.

52-Week Low
52-Week High
16.41
331.68

Overview:

Market Capitalization, $K 13,275,418
Shares Outstanding, K 73,859
Last Quarter Sales 279,660 K
Last Quarter Net Income -177,560 K
% Insider Shareholders 3.30%
% Institutional Shareholders 52.59%

Merck & Company (MRK)

Full Profile

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.

52-Week Low
52-Week High
71.71
87.80

Overview:

Market Capitalization, $K 193,093,904
Shares Outstanding, K 2,530,388
Last Quarter Sales 12,514 M
Last Quarter Net Income -2,095 M
% Insider Shareholders 0.28%
% Institutional Shareholders 73.72%

Johnson & Johnson (JNJ)

Full Profile

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.

52-Week Low
52-Week High
133.65
173.65

Overview:

Market Capitalization, $K 424,524,000
Shares Outstanding, K 2,632,707
Last Quarter Sales 22,475 M
Last Quarter Net Income 1,738 M
% Insider Shareholders 0.30%
% Institutional Shareholders 68.30%

Amgen Inc (AMGN)

Full Profile

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

52-Week Low
52-Week High
210.28
276.69

Overview:

Market Capitalization, $K 143,345,904
Shares Outstanding, K 575,802
Last Quarter Sales 6,634 M
Last Quarter Net Income 1,615 M
% Insider Shareholders 0.36%
% Institutional Shareholders 75.72%

Rogers Corp (ROG)

Full Profile

Rogers Corporation is a global leader in engineered materials to power, protect, and connect their world. With more than 180 years of materials science experience, Rogers delivers high-performance solutions that enable clean energy, internet connectivity, and safety and protection applications, as well as other technologies where reliability is critical. Rogers delivers Power Electronics Solutions for energy-efficient motor drives, e-Mobility and renewable energy; Elastomeric Material Solutions for sealing, vibration management and impact protection in mobile devices, transportation interiors, industrial equipment and performance apparel; and Advanced Connectivity Solutions for wireless infrastructure, automotive safety and radar systems. Headquartered in Arizona (USA), Rogers operates manufacturing facilities in the United States, China, Germany, Belgium, Hungary, and South Korea, with joint ventures and sales offices worldwide.

52-Week Low
52-Week High
92.01
199.50

Overview:

Market Capitalization, $K 3,625,019
Shares Outstanding, K 18,677
Last Quarter Sales 210,670 K
Last Quarter Net Income 15,210 K
% Insider Shareholders 0.90%
% Institutional Shareholders 95.63%

Adaptive Biotechnologies Corp (ADPT)

Full Profile

Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington.

52-Week Low
52-Week High
24.27
71.25

Overview:

Market Capitalization, $K 5,627,231
Shares Outstanding, K 139,219
Last Quarter Sales 30,190 K
Last Quarter Net Income -44,570 K
% Insider Shareholders 34.70%
% Institutional Shareholders 81.81%

Regeneron Pharmaceuticals (REGN)

Full Profile

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.

52-Week Low
52-Week High
441.00
664.64

Overview:

Market Capitalization, $K 50,905,916
Shares Outstanding, K 107,132
Last Quarter Sales 2,423 M
Last Quarter Net Income 1,149 M
% Insider Shareholders 11.84%
% Institutional Shareholders 84.35%

Gilead Sciences Inc (GILD)

Full Profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

52-Week Low
52-Week High
56.56
85.79

Overview:

Market Capitalization, $K 81,977,136
Shares Outstanding, K 1,259,056
Last Quarter Sales 7,421 M
Last Quarter Net Income 1,551 M
% Insider Shareholders 0.13%
% Institutional Shareholders 77.10%

Acadia Pharmaceutica (ACAD)

Full Profile

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.

52-Week Low
52-Week High
20.12
58.72

Overview:

Market Capitalization, $K 3,263,358
Shares Outstanding, K 160,047
Last Quarter Sales 121,010 K
Last Quarter Net Income -66,760 K
% Insider Shareholders 27.70%
% Institutional Shareholders 92.37%

Incyte Corp (INCY)

Full Profile

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.

52-Week Low
52-Week High
75.52
110.36

Overview:

Market Capitalization, $K 17,578,724
Shares Outstanding, K 219,844
Last Quarter Sales 789,510 K
Last Quarter Net Income 149,850 K
% Insider Shareholders 16.10%
% Institutional Shareholders 92.47%

Biogen Inc (BIIB)

Full Profile

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.

52-Week Low
52-Week High
223.25
363.92

Overview:

Market Capitalization, $K 40,851,944
Shares Outstanding, K 152,336
Last Quarter Sales 2,853 M
Last Quarter Net Income 357,900 K
% Insider Shareholders 0.54%
% Institutional Shareholders 84.54%

Arena Pharmaceuticals (ARNA)

Full Profile

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.

52-Week Low
52-Week High
44.79
90.19

Overview:

Market Capitalization, $K 3,999,607
Shares Outstanding, K 60,335
Last Quarter Sales 40 K
Last Quarter Net Income -122,160 K
% Insider Shareholders 3.05%
% Institutional Shareholders 89.91%

Ligand Pharm (LGND)

Full Profile

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.

52-Week Low
52-Week High
78.26
219.75

Overview:

Market Capitalization, $K 2,548,944
Shares Outstanding, K 16,612
Last Quarter Sales 69,990 K
Last Quarter Net Income 5,760 K
% Insider Shareholders 10.60%
% Institutional Shareholders N/A

Crispr Therapeutics Ag (CRSP)

Full Profile

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

52-Week Low
52-Week High
42.83
220.20

Overview:

Market Capitalization, $K 8,730,152
Shares Outstanding, K 75,429
Last Quarter Sales 370 K
Last Quarter Net Income -107,040 K
% Insider Shareholders 21.40%
% Institutional Shareholders 62.41%

Bluebird Bio (BLUE)

Full Profile

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.

52-Week Low
52-Week High
24.24
72.50

Overview:

Market Capitalization, $K 1,890,690
Shares Outstanding, K 67,141
Last Quarter Sales 10,710 K
Last Quarter Net Income -199,870 K
% Insider Shareholders 3.60%
% Institutional Shareholders 92.61%

Vir Biotechnology Inc (VIR)

Full Profile

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.

52-Week Low
52-Week High
25.31
141.01

Overview:

Market Capitalization, $K 5,519,993
Shares Outstanding, K 127,985
Last Quarter Sales 1,730 K
Last Quarter Net Income -105,650 K
% Insider Shareholders 37.20%
% Institutional Shareholders 61.82%

Cytodyn Inc (CYDY)

Full Profile

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.

52-Week Low
52-Week High
1.6300
10.0100

Overview:

Market Capitalization, $K 1,918,158
Shares Outstanding, K 612,830
Last Quarter Sales N/A
Last Quarter Net Income N/A
% Insider Shareholders 7.80%
% Institutional Shareholders 0.12%
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar